Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Quest AD-Detect Tests Show Accuracy In Alzheimer’s Diagnosis
A new study published in Neurology Clinical Practice, the journal of the American Academy of Neurology, has found that two blood tests using multiple biomarkers are very accurate in finding Alzheimer’s disease in people who show symptoms. These tests can help doctors make a diagnosis of Alzheimer’s and might cut down on the need for more invasive or expensive tests like amyloid PET scans or spinal fluid tests.
SimBioSys Featured for AI 3D Breast Cancer Surgery Tools
SimBioSys, a precision medicine company using artificial intelligence to improve cancer care, announced that its FDA-cleared TumorSight Viz technology was recently featured on ABC News Digital and Good Morning America. The coverage highlighted how AI-powered 3D visualization helps surgeons and patients make more informed decisions about breast cancer surgery.
Dispersive Achieves HIPAA Compliance for Healthcare Security
Dispersive Holdings, Inc., a leading company in stealth networking and secure communications that work even after quantum computers are developed, announced that it has finished an independent audit to check if it follows HIPAA rules. This audit was done by Johanson Group LLP and looked at their virtual networking platform to make sure it properly keeps electronic protected health information, or ePHI, safe.
BioDlink Completes First International Shipment of Bevacizumab to Colombia
BioDlink has successfully shipped its first international batch of bevacizumab injection biosimilar to Colombia, working together with Kexing BioPharm. This achievement was marked by a special event with decorated delivery trucks to celebrate the milestone. Bevacizumab is a type of monoclonal antibody that targets vascular endothelial growth factor, and it’s used to treat several types of cancer, including metastatic colorectal cancer and some lung cancers. In 2023, this drug generated over 8.5 billion USD in global sales, showing how important it is in cancer treatments.
HyHub and HyHub Duo Now Available in U.S. for HYQVIA Use
Takeda announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are prescribed HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]. The dedicated devices allow HYQVIA, a facilitated subcutaneous immunoglobulin (SCIg) infusion comprised of dual vial units (DVUs) of immunoglobulin and hyaluronidase, to be transferred from vials without using a needle or pooling bag in a home environment or clinical setting. HyHub and HyHub Duo simplify HYQVIA administration by reducing the number of steps to prepare the infusion of two DVUs or more.
To share your insights, please write to us at info@intentamplify.com
